SCHEMBL1719929

SCHEMBL1719929

Cc1ccc2cc(N)[nH]c(=O)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMS P04818 2/20 0.50
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 3/20 0.43
GAA P10253 2/20 0.43
LMNA P02545 2/20 0.43
HPGD P15428 1/20 0.43
CDC25B P30305 1/20 0.43
UBE2I P63279 1/20 0.43
SAE1 Q9UBE0 1/20 0.43
UBA2 Q9UBT2 1/20 0.43
DAO P14920 2/20 0.42
DDO Q99489 1/20 0.42
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2A6 P11509 2/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL824649 0.81 KDM4E (0.63) TYMSKDM4EALDH1A1HSD17B10GAA
SCHEMBL1720303 0.78 TYMS (0.50) TYMSKDM4EALDH1A1GAAHPGD
SCHEMBL1720595 0.78 TYMS (0.50) TYMSKDM4ELMNADAOTUBB4A
SCHEMBL6646013 0.78 SAE1 (0.46) TYMSKDM4EALDH1A1HSD17B10GAA
SCHEMBL14867343 0.75 HPGD (0.57) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL1719778 0.75 LOXL2 (0.61) KDM4EALDH1A1GAALMNAHPGD
SCHEMBL29844316 0.75 LOXL2 (0.61) KDM4EALDH1A1GAALMNAHPGD
SCHEMBL30160749 0.73 KDM4E (0.59) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL28629567 0.73 KDM4E (0.59) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL8959176 0.72 AOC3 (0.54) KDM4EALDH1A1HSD17B10GAADAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 TYMS 1123/4885KDM4E 3585/4885ALDH1A1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.